Table of Contents x-ix
Preface xiv
Andrew R. Marks
Columbia University Colleges of Physicians and Surgeons, New York, USA.
PART 1 – CELL DEATH
1Pharmacological manipulation of cell death: clinical applications in sight?
Guido Kroemer and Douglas Green
Center for National Scientific Research, Villejif Cedex, France.
2Pharmacological manipulation of Bcl-2 family members to control cell death
Anthony G. Letai
HarvardUniversity, Cambridge, Massachusetts, USA.
3Caspases: Pharmacological manipulation of cell death
Inna N. Lavrik, Alexander Golks, and Peter H. Krammer
GermanCancerResearchCenter, Heidelberg, Germany.
4IKK/NF-B signaling: balancing life and death– a new approach to cancer therapy
Jun-Li Luo, Hideaki Kamata, and Michael Karin
University of California, San Diego, La Jolla, California, USA.
5Reawakening the cellular death program in neoplasia through
therapeutic blockade of IAP function
Casey W. Wright and Colin Duckett
University of Michigan, Ann Arbor, Michigan, USA.
6The survival kinases Akt and Pim as potential pharmacologic targets
Ravi Amaravadi and Craig Thompson
University of Pennsylvania, Philadelphia, Pennsylvania, USA.
7Mitochondria: pharmacological manipulation of cell death
Lisa Bouchier-Hayes, Lydia Lartigue, and Donald Newmeyer
La Jolla Institute for Allergies and Immunology, San Diego, California, USA.
8Death versus survival: functional interaction between the apoptotic and
stress-inducible heat shock protein pathways
Helen M. Beere
La Jolla Institute for Allergies and Immunology, San Diego, California, USA.
9Autophagy in cell death: an innocent convict?
Beth Levine and Junying Yuan
University of Texas Southwestern MedicalCenter, Dallas, Texas, USA.
10Endoplasmic reticulum stress: cell life and death decisions
Chunyan Xu, Beatrice Bailly-Maitre, and John Reed
The Burnham Institute, La Jolla, California, USA.
PART 2 – ONCOLOGY
11Dysregulation of Met receptor tyrosine kinase activity in invasive tumors
Alla Danilkovitch-Miagkova and Berton Zbar
National Cancer Institute, NIH, Bethesda, Maryland, USA.
12 Integrins in invasive growth
Cord Brakebusch, Daniel Bouvard, Fabio Stanchi, Takao Sakai, and Reinhard Fässler
LundUniversity, Lund, Sweden.
13Stat proteins and oncogenesis
Jacqueline Bromberg
Memorial Sloan Kettering Cancer Center, New York, USA.
14The cadherin-catenin adhesion system in signaling and cancer
Maralice Conacci-Sorrell, Jacob Zhurinsky, and Avri Ben-Ze’ev
Weismann Institute, Rehovot, Israel.
15 Do tumor-suppressive mechanisms contribute to organism aging by inducing
stem cell senescence?
Pier Giuseppe Pelicci
European Institute of Oncology, Milan, Italy.
16When cells get stressed: an integrative view of cellular senescence
Ittai Ben-Porath and Robert A. Weinberg
The Whitehead Institute, Cambridge, Massachusetts, USA.
17Telomeres, stem cells, senescence, and cancer
Norman E. Sharpless and Ronald A. DePinho
Dana Farber Cancer Institute, Boston, Massachusetts, USA.
18Bmi1, stem cells, and senescence regulation
In-KyungPark, Sean J. Morrison, and Michael F. Clarke
University of Michigan, Ann Arbor, Michigan, USA.
19Cellular senescence in cancer treatment: friend or foe?
Pascal Kahlem, Bernd Dörken, and Clemens A. Schmitt
MaxDelbruckCenter for Molecular Medicine, Berlin, Germany.
20 Mechanisms for pituitary tumorigenesis: the plastic pituitary
Shlomo Melmed
Cedars-SinaiMedicalCenter, Los Angeles, California, USA.
21Melanoma genetics and the development of rational therapeutics
Yakov Chudnovsky, Paul A. Khavari, and Amy E. Adams
Stanford University School of medicine, Stanford, California, USA.
22Immunopathogenesis and therapy of cutaneous T cell lymphoma
Ellen J. Kim, Stephen Hess, Stephen K. Richardson, Sara Newton, Bernice M. Benoit, Ravi Ubriani, Carmela C. Vittorio, Jacqueline M. Junkins-Hopkins, Maria Wysocka, Alain H. Rook
23Cancer vaccines: progress reveals new complexities
Zhiya Yu and Nicholas P. Restifo
National Cancer Institute, NIH, Bethesda, Maryland, USA.
PART 3 –IMMUNE SYSTEM and IMMUNE-MEDIATED INJURY
24IFNs and STATs in innate immunity to microorganisms
Thomas Decker, Silvia Stockinger, Marina Karaghiosoff, Mathias Müller, and Pavel Kovarik
Vienna Biocenter, Vienna, Austria.
25Molecular aspects of primary immunodeficiencies: lessons from cytokine and
other signaling pathways
Fabio Candotti, Luigi Notarangelo, Roberta Visconti, and John O’Shea
National Human Genome Research Institute, NIH, Bethesda, Maryland, USA.
26An integrated view of suppressor T cell subsets in immunoregulation
Hong Jiang and Leonard Chess
ColumbiaUniversityCollege of Physicians and Surgeons, New York, USA.
27CD4+ Tregs and immune control
Zoltán Fehérvari and Shimon Sakaguchi
KyotoUniversity, Kyoto, Japan.
28Tregs and allergic disease
Douglas S. Robinson, Mark Larché, and Stephen R. Durham
ImperialCollege, London, Great Britain.
29Tregs and transplantation tolerance
Patrick T. Walsh, Devon K. Taylor, and Laurence A. Turka
University of Pennsylvania, Philadelphia, Pennsylvania, USA.
30C-reactive protein: a critical update
Mark Pepys and Gideon Hirschfield
Royal Free and UniversityCollegeMedicalSchool, London, United Kingdom.
31New insights into atopic dermatitis
Donald Y.M. Leung, Mark Boguniewicz, Michael D. Howell, Ichiro Nomura,
and Qutayba A. Hamid
National Jewish Center, Denver, Colorado, USA.
32Recent insights into the immunopathogenesis of psoriasis provide
new therapeutic opportunities
Brian J. Nickoloff and Frank O. Nestle
LoyolaUniversityMedicalCenter, Maywood, Illinois, USA.
University of ZurichMedicalSchool, Zurich, Switzerland.
33Exploiting dendritic cells to improve vaccine efficacy
Ralph M. Steinman and Melissa Pope
Rockefeller University, New York, USA.
PART 4 – INFECTIOUS DISEASES
Clinical Syndromes
34The enigma of sepsis
Niels C. Riedemann, Ren-Feng Guo, and Peter A. Ward
University of Michigan, Ann Arbor, Michigan, USA.
Gram-positive bacteria in health and disease
35Antimicrobial resistance: the example of Staphylococcus aureus
Franklin D. Lowy
ColumbiaUniversityCollege of Physicians and Surgeons, New York, USA.
36Bacterial infectious disease control by vaccine development Roy Curtiss, III
WashingtonUniversity, St. Louis, Missouri, USA
.
37Development of an improved vaccine for anthrax
Stephen H. Leppla, John B. Robbins, Rachel Schneerson, and Joseph Shiloach
National Institutes of Health, Bethesda, Maryland, USA.
Gram-negative bacteria in health and disease
38Helicobacter pylori persistence: biology and disease
Martin J. Blaser and John C. Atherton
New York University Medical Center, New York, USA.
39The emergence of Lyme disease
Allen C. Steere, Jenifer Coburn, and Lisa Glickstein
TuftsUniversity, Boston, Massachusetts, USA.
Bacterial communication
40The application of biofilm science to the study and control of chronic
bacterial infections
William Costerton, Richard Veeh, Mark Shirtliff, Mark Pasmore,
Christopher Post, and Garth Ehrlich
Montana State University, Montana, USA.
41Quorum sensing in Staphylococcus infections
Jeremy M. Yarwood and Patrick M. Schlievert
University of Minnesota, Minneapolis, Minnesota, USA.
42Quorum sensing and biofilm formation in Streptococcal infections
Dennis G. Cvitkovitch, Yung-Hua Li, and Richard P. Ellen
University of Toronto, Toronto, Ontario, Canada.
43Pharmacological inhibition of quorum sensing for the treatment of chronic bacterial infections
Morten Hentzer and Michael Givskov
Technical University of Denmark, Lyngby, Denmark.
44Pseudomonas aeruginosa quorum sensing as a potential antimicrobial target 20364
Roger S. Smith and Barbara H. Iglewski
University of Rochester, Rochester, New York, USA.
Protozoal Infections
45Antimalarial drug resistance
Nicholas J. White
MahidolUniversity, Bangkok, Thailand.
Parasitic infections
46Human African trypanosomiasis of the CNS: current issues and challenges
Peter G.E. Kennedy
University of Glasgow, Glasgow, Scotland.
PART 5 –VIRAL DISEASES
47SARS coronavirus: a new challenge for prevention and therapy
Kathryn Holmes
University of ColoradoHealthScienceCenter, Denver, Colorado, USA.
48Acute HIV revisited: new opportunities for treatment and prevention
Christopher D. Pilcher, Joseph J. Eron Jr., Shannon Galvin, Cynthia Gay, and Myron S. Cohen
University of North Carolina, Chapel Hill, North Carolina, USA.
49Strategies for an HIV vaccine
Norman L. Letvin
HarvardUniversity, Boston, Massachusetts, USA.
50Dengue: defining protective versus pathologic immunity
Alan L. Rothman
University of Massachusetts, Worcester, MassachusettsUSA.
51West Nile virus: a growing concern?
L. Hannah Gould and Erol Fikrig
YaleUniversitySchool of Medicine, New Haven, Connecticut, USA.
52Progress on new vaccine strategies against chronic viral infections Jay A. Berzkofsky, Jeffrey D. Ahlers, John Janik, John Morris, SangKon Oh, Masaki Terabe,
and Igor M. Belyakov
National Cancer Institute, NIH, Bethesda, Maryland, USA.
53Parainfluenza virus entry into cells as a target for interrupting
childhood respiratory disease
Anne Moscona
Mount Sinai School of Medicine, New York, USA.
54Influenza vaccines: present and future Peter Palese and Adolfo García-Sastre
Mount Sinai School of Medicine, New York, USA.
55Live-attenuated virus vaccines for respiratory syncytial and parainfluenza viruses: applications of reverse genetics
Brian R. Murphy and Peter L. Collins
National Institute for Allergy and Infectious diseases, NIH, Bethesda, Maryland, USA.
56Herpes simplex viruses: is a vaccine tenable?
Richard J. Whitley and Bernard Roizman
University of Chicago, Chicago, Illinois, USA.
57Prophylactic human papillomavirus vaccines
Douglas R. Lowy and John T. Schiller
National Cancer Institute, NIH, Bethesda, Maryland, USA.
PART 6 – RESPIRATORY SYSTEM
58Disorders of lung matrix remodeling
Harold A. Chapman
University of California, San Francisco, California, USA.
59New insights into the pathogenesis of asthma
Jack A. Elias, Chun Geun Lee, Tao Zheng, Bing Ma, Robert J. Homer, and Zhou Zhu
YaleUniversitySchool of Medicine, New Haven, Connecticut, USA.
60JAK-STAT signaling in asthma
Alessandra B. Pernis and Paul B. Rothman
ColumbiaUniversityCollege of Physicians and Surgeons, New York, USA.
61Rescuing protein conformation: prospects for pharmacological therapy
in cystic fibrosis
Marina S. Gelman and Ron R. Kopito
StanfordUniversityMedicalCenter, Stanford, California, USA.
62Epithelial-mesenchymal transition and its implications for fibrosis
Raghu Kalluri and Eric G. Neilson
HarvardUniversity, Cambridge, Massachusetts, USA.
PART 7 – CARDIOVASCULAR SYSTEM
63Oxygen, oxidative stress, hypoxia, and heart failure
Frank J. Giordano
YaleUniversity, New Haven, Connecticut, USA.
64NO/redox disequilibrium in the failing heart and cardiovascular system
Joshua M. Hare and Jonathan S. Stamler
DukeUniversityMedicalCenter, Durham, North Carolina, USA.
65Genetic causes of human heart failure
Hiroyuki Morita, Jonathan Seidman, and Christine E. Seidman
HarvardUniversity, Boston, Massachusetts, USA.
66Protein kinase cascade in the regulation of cardiac hypertrophy
Gerald W. Dorn II and Thomas Force
University of Cincinnati, Cincinnati, Ohio, USA.
67Toward transcriptional therapies for the failing heart: chemical screens
to modulate genes
Timothy A. McKinsey and Eric N. Olson
University of Texas Southwestern MedicalCenter, Dallas, Texas, USA.
68Mitochondrial energy metabolism in heart failure: a question of balance
Janice M. Huss and Daniel P. Kelly
WashingtonUniversity, St. Louis, Missouri, USA.
69Death begets heart failure
Roger S.-Y. Foo, Kartik Mani, and Richard N. Kitsis
Albert Einstein College of Medicine, New York, USA.
70Unchain my heart: the scientific foundations of cardiac repair
Stefanie Dimmeler, Andreas M. Zeiher, and Michael D. Schneider
University of FrankfurtFrankfurt, Germany
BaylorCollege of Medicine, Houston, Texas, USA.
71Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities
Garret A. Fitzgerald
University of Pennsylvania, Philadelphia, Pennsylvania, USA.
72Sex is a potent modifier of the cardiovascular system
Leslie Leinwand
University of Colorado, Boulder, Colorado, USA.
Vascular Diseases
73Cholesterol in health and disease
Ira Tabas
ColumbiaUniversityCollege of Physicians and Surgeons, New York, USA.
74Cholesterol, lipid rafts, and disease
Kai Simons and Robert Ehehalt
Max Planck Instittue of Molecular medicine, Dresden, Germany.
75Malformation syndromes due to inborn errors of cholesterol synthesis
Forbes D. Porter
National Institutes of Health, Bethesda, Maryland, USA.
76Intracellular cholesterol transport
Frederick R. Maxfield and Daniel Wüstner
Cornel University Medical College, New York, USA.
77Regulation and mechanisms of macrophage cholesterol efflux
Alan R. Tall, Philippe Costet, and Nan Wang
ColumbiaUniversityCollege of Physicians and Surgeons, New York, USA.
78Consequences of cellular cholesterol accumulation: basic concepts and physiological implications
Ira Tabas
ColumbiaUniversityCollege of Physicians and Surgeons, New York, USA.
79Monogenic hypercholesterolemia: new insights in pathogenesis and treatment
Daniel J. Rader, Jonathan Cohen, and Helen H. Hobbs
University of Pennsylvania, Philadelphia, Pennsylvania, USA.
University of Texas Southwestern MedicalCenter, Dallas, Texas, USA.
80Isoprenoids as mediators of the biological effects of statins
James K. Liao
HarvardUniversity, Cambridge, Massachusetts, USA.
Disorders of rhythm
81The channelopathies: novel insights into molecular and genetic
mechanisms of human disease
Robert Kass
Columbia University Colleges of Physicians and Surgeons, New York, USA.
82Mechanisms of sudden cardiac death
Michael Rubart and Douglas P. Zipes
Krannert Institute of Cardiology, Indianapolis, Indiana, USA.
83Long QT syndrome: from channels to cardiac arrhythmias
Arthur J. Moss and Robert Kass
University of RochesterMedicalCenter, Rochester, New York, USA.
84Genetics of acquired long QT syndrome
Dan M. Roden
VanderbiltUniversity, Nashville, Tennessee, USA.
85Muscle channelopathies and critical points in functional and genetic studies
Karin Jurkat-Rott and Frank Lehmann-Horn
UlmUniversity, Ulm, Germany
86Inherited disorders of voltage-gated sodium channels
Alfred L. George, Jr.
VanderbiltUniversity, Nashville, Tennessee, USA.
87Cardiac and skeletal muscle disorders caused by mutations in the
intracellular Ca2+-release channels
Silvia G. Priori and Carlo Napolitano
University of Pavia, Pavia, Italy.
88Chloride channel diseases resulting from impaired transepithelial
transport or vesicular function
Thomas J. Jentsch, Tanja Maritzen, and Anselm A. Zdebik
PART 8 –HEMATOLOGY
89Megakaryocyte biology and related disorders
Liyan Pang, Mitchell J. Weiss, and Mortimer Poncz
Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
90The molecular mechanisms that control thrombopoiesis
Kenneth Kaushansky
University of California, San Diego, California, USA.
91Thrombus formation in vivo
Bruce Furie and Barbara C. Furie
BethIsraelDeaconessMedicalCenter, HarvardUniversity. Boston, Massachusetts, USA.
92Platelet genomics and proteomics in human health and disease
Ian C. Macauley, Philippa Carr, Arief Gusnanto, Willem H. Ouwehand,
Des Fitzgerald, and Nicholas A. Watkins
UniversityCollegeDublin, Dublin, Ireland.
93The biogenesis of platelets from megakaryocyte proplatelets
Sunita R. Patel, John H. Hartwig, and Joseph Italiano
HarvardUniversity, Cambridge, Massachusetts, USA.
94Platelets in inflammation and atherogenesis
Meinrad Gawaz, harald Langer, and Andreas E. May
MunichTechnicalUniversity, Munich, Germany.
95Structure and function of the platelet integrin IIb3
Joel S. Bennett
University of Pennsylvania, Philadelphia, USA.
96Minding the gaps to promote thrombus growth and stability
Lawrence F. Brass, Li Zhu, and Timothy J. Stalker
University of Pennsylvania, Philadelphia, Pennsylvania, USA.
97Untying the Gordian knot: policies, practices, and ethical issues related to
banking of umbilical cord blood
Joanne Kurtzberg
DukeUniversity, Durham, North Carolina, USA.
PART 9 – GASTROINTESTINAL SYSTEM
98Intestinal ion transport and the pathophysiology of diarrhea
Michael Field
Columbia University Colleges of Physicians and Surgeons, New York, USA.
99Molecular mediators of hepatic steatosis and liver injury
Jeffrey D. Browning and Jay D. Horton
University of Texas Southwestern MedicalCenter, Dallas, Texas, USA.
100Liver fibrosis
Ramón Bataller and David A. Brenner
Columbia University Colleges of Physicians and Surgeons, New York, USA.
101 SREBPs: activators of the complete program of cholesterol and
fatty acid synthesis in the liver
Jay D. Horton, Joseph L. Goldstein, and Michael S. Brown
University of Texas Southwestern MedicalCenter, Dallas, Texas, USA.
PART 10 –ENDOCRINOLOGY AND METABOLISM
102Genetic epidemiology of diabetes
M. Alan. Permutt, Jonathan Wasson, and Nancy Cox
WashingtonUniversity. St. Louis, USA.
103ATP-sensitive potassium channelopathies: focus on insulin secretion
Frances M. Ashcroft
University of Oxford, Oxford, Great Britain.
104Gestational diabetes mellitus
Thomas A. Buchanan and Anny H. Xiang
University of Southern California, Los Angeles, California, USA.
105Regeneration of the pancreatic cell
Massimo Trucco
University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
106Challenges facing islet transplantation for the treatment of
type 1 diabetes mellitus
Kristina I. Rother and David M. Harlan
National Institute of Diabetes and Digestive and Kidney Diseases, NIH, Bethesda, Maryland, USA.
107How does blood glucose control with insulin save lives in intensive care?
Greet Van den Berghe
KatholiekeUniversityLueven, Belgium.
108Thyrotropin receptor–associated diseases: from adenomata to Graves’ disease
Terry F. Davies, Takao Ando, Reigh-Yi Lin, Yaron Tomer and Rauf Latif
Mount Sinai School of Medicine, New York, USA.
109Inflammation, stress, and diabetes
Kathryn E. Wellen and Gökhan S. Hotamisligil
Harvard School of Public Health, Boston, Massachusetts, USA.
110Adiponectin and adiponectin receptors in insulin resistance,
diabetes, and the metabolic syndrome
Takashi Kadowaki, Toshimasa Yamauchi, Naoto Kubota, Kazuo Hara, Kohjiro Ueki, and Kazuyuki Tobe
University of Tokyo and National Institute of Health and Nutrition, Tokyo, Japan.
111The role of cholesterol efflux in regulating the fertilization potential of mammalian spermatozoa
Alexander J. Travis and Gregory S. Kopf
Wyeth, Philadelphia, Pennsylvania, USA.
112Trophoblast differentiation during embryo implantation and formation of
the maternal-fetal interface
Susan Fisher
University of Califronia, San Francisco, California, USA.
PART 11 – KIDNEY AND URINARY TRACT
113Acute renal failure: definitions, diagnosis, pathogenesis, and therapy R.W. Schrier, W. Wang, B. Poole, and A. Mitra
University of Colorado, Denver, Colorado, USA.
114Kidney stone disease
Fredric L. Coe, Andrew Evan, and Elaine Worcester
University of Chicago, Chicago, Illinois, USA.
115Salt handling and hypertension
Kevin M. O’Shaughnessy and Fiona E. Karet
Cambridge Institute of Medical Research, Cambridge, England, Great Britain.
PART 12 – BONE AND MINERAL METABOLISM
116Pathogenesis of osteoporosis: concepts, conflicts, and prospects
Lawrence G. Raisz
University of Connecticut, Farmington, Connecticut, USA.
117Paget disease of bone
G. David Roodman and Jolene J. Windle
University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
118Estrogen deficiency and bone loss: an inflammatory tale
M. Neale Weitzmann and Roberto Pacifici
EmoryUniversity, Atlanta, Georgia, USA.
119Regulation of bone mass by Wnt signaling
Venkatesh Krishnan, Henry U. Bryant, and Ormond A. MacDougald
Lily Research laboratories, Indianapolis, Indiana, USA
Univeristy of Michigan, Ann Arbor, Michigan, USA.
PART 13 –NEUROLOGIC DISORDERS
120VEGF: A critical player in neurodegeneration
Erik Strorkebaum and Peter Carmeliet
KatholiekeUniversityLueven, Belgium.
121Neurogenesis and brain injury: managing a renewable source for repair
Daniel Peterson
RosalindFranklinUniversity of Medicine and Science, North Chicago, Illinois, USA.
122Oxidative stress, cell cycle, and neurodegeneration
Jeffrey A. Klein and Susan L. Ackerman
The Jackson Laboratory, Bar Harbor, Maine, USA.
123Neuronal degeneration and mitochondrial dysfunction
Eric A. Schon and Giovanni Manfredi
Columbia University Colleges of Physicians and Surgeons, New York, USA.
124The role of cerebral A accumulation in common forms of Alzheimer disease
Sam Gandy
ThomasJeffersonUniversity, Philadelphia, Pennsylvania, USA.
125Alzheimer disease therapy: Can the amyloid cascade be halted?
Todd E. Golde
Mayo Clinic, Jacksonville, Florida.
126Diagnosis and treatment of Parkinson disease: molecules to medicine
Joseph M. Savitt, Valina L. Dawson, and Ted M. Dawson
JohnsHopkinsSchool of Medicine, Baltimore, Maryland, USA.
127Huntingtin in health and disease
Anne B. Young
Massachusetts GeneralHospital, Boston, Massachusetts, USA.
128Programmed cell death in amyotrophic lateral sclerosis
Christelle Guégan and Serge Przedborski
ColumbiaUniversityCollege of Physicians and Surgeons, New York, USA.
129Multiple sclerosis
David A. Hafler
Brigham and Women’s Hospital, Harvard University, Boston, Massachusetts, USA.